Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients

PURPOSE: Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare genetic syndrome resulting from germline mutations in fumarate hydratase. The combination of bevacizumab plus erlotinib showed promising interim results for HLRCC-associated RCC. Based on these results, we analyzed the out...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer Res Treat
Главные авторы: Choi, Yeonjoo, Keam, Bhumsuk, Kim, Miso, Yoon, Shinkyo, Kim, Dalyong, Choi, Jong Gwon, Seo, Ja Young, Park, Inkeun, Lee, Jae Lyun
Формат: Artigo
Язык:Inglês
Опубликовано: Korean Cancer Association 2019
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6790829/
https://ncbi.nlm.nih.gov/pubmed/30913859
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2019.086
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы